Scientists found that a combination of special agents that boost our immune system and immune proteins. These act like “checkpoints” and can be a powerful treatment for mesothelioma.
Mesothelioma is a serious cancer affecting the lining of organs. When it grows in the lining of the lungs, it is called pleural mesothelioma. Mesothelioma is caused by breathing in tiny asbestos fibers. This can happen if you are exposed to old buildings or products containing asbestos.
Scientists have been working hard to find better ways to treat this disease and may have made an important discovery.The conventional treatment for mesothelioma is a combination of surgery, chemotherapy, or radiation. Doctors might also recommend immunotherapy for their patients. This is a type of treatment that uses the patient’s immune system to treat the cancer tissue.
How Mesothelin Could Be the Key to Beating Mesothelioma
Scientists have found that using two special substances can effectively treat mesothelioma. They are called mesothelin and anti-PD-L1 antibody-drug conjugates. These target the cancer cells and stop them from spreading, while also helping the immune system get back on track.
To test this, the scientists studied 82 cases of mesothelioma in one group and 87 cases in another. They looked at patient tissue samples. They used special techniques to see how mesothelin and other important factors were connected.
The scientists found that the levels of mesothelin in the tumors were important to treatment outcomes. When they found high levels of mesothelin in the tissue sample, the scientists were also likely to find proteins. These proteins could help the body with its immune system response. This means that mesothelin could be a crucial target for new treatments that use our own immune system to fight mesothelioma.
This study is a big step forward in finding better treatments for mesothelioma. By combining mesothelin and immune proteins, scientists are giving new hope to patients with this aggressive cancer.
Capelozzi VL, Qualiotto AN, Baldavira CM, Balancin M, Ab’Saber A, Takagaki T. Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma. Front Immunol. 2023;14. doi: 10.3389/fimmu.2023.1268927. https://www.frontiersin.org/articles/10.3389/fimmu.2023.1268927/abstract